Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled study of camostat mesilate in
ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.